Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » antisense

antisense

Feb 04, 2021

RNA Disease Diagnostics to Develop Point-of-Care Coronavirus Test With Newly Licensed Tech

The company said it intends to use the technology to develop infectious disease diagnostics, with an initial focus on SARS-CoV-2.

Oct 01, 2020

Genuity Science, Ionis Pharmaceuticals Partner on Antisense Therapy Development

Genuity Science, formerly known as WuXi NextCode, will receive a combination of upfront, development milestone, and product royalty payments under the deal.

Sep 04, 2020

Science Papers on Crystal Structure of Bacteriophages, Silencing of ALS-Linked Gene

In Science this week: crystal structures of single-stranded RNA bacteriophages found through metagenomic studies, more.

Jun 30, 2020

PNAS Papers on DMD, Muscular Dystrophy Gene Knockdown, More

In PNAS this week: effect of premature termination codons in the DMD gene, knock-down of DUX4 in facioscapulohumeral muscular dystrophy, and more.

Jan 10, 2020

Empirico Inks Drug Target Discovery Alliance With Antisense Drug Firm Ionis

As part of the deal, Ionis also took a $10 million equity stake in Empirico and was the lead investor in the company's Series A-2 financing round.

Sep 11, 2018

UMich Researcher Wins $6.5M NCI Outstanding Investigator Award

UMich's Arul Chinnaiyan plans to use the funding to develop new tools and technologies to identify biomarkers for cancer diagnosis and treatment.

Jan 09, 2015

Alnylam, Isis Ink IP Licensing Deal

Premium

The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.

Oct 30, 2014

Isis Negotiating Settlement of Santaris Litigation with Roche

Premium

NEW YORK (GenomeWeb) — Isis Pharmaceuticals and Santaris Pharma are currently negotiating a settlement to their roughly three-year-old patent-infringement lawsuit and believe there is "strong potential to settle" the litigation instead of going to trial, according to court documents filed this mo

Oct 09, 2014

Lakewood-Amedex Looks to Restart Antisense Efforts Beginning with Flu

Premium

NEW YORK (GenomeWeb) – While its primary focus remains on a class of novel cell membrane-disrupting antimicrobials, privately held Lakewood-Amedex is ramping up work on proprietary, orally delivered antisense molecules, with an eye to tackling influenza and, eventually, other viral diseases.

Aug 21, 2014

Looking to Restart Operations, Marina Regains Compliance with SEC Reporting Rules

Premium

NEW YORK (GenomeWeb) – Marina Biotech this week took another step toward reestablishing itself as a player in the nucleic acids drug sector, regaining compliance with US Securities and Exchange Commission financial reporting requirements with the submission of the requisite information for 2012,

Pages

The Scan

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Support for Another

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

New Prototype Test

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

Cell Studies on SARS-CoV-2 Spike Variant, Host Transcriptomes, Glioma-Infiltrating T Cells

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.